Elevation Oncology Inc (NASDAQ:ELEV) price on Friday, June 13, rose 0.39% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.38.
A look at the stock’s price movement, the close in the last trading session was $0.38. Turning to its 52-week performance, $3.44 and $0.22 were the 52-week high and 52-week low respectively. Overall, ELEV moved 11.74% over the past month.
Elevation Oncology Inc’s market cap currently stands at around $22.61 million, with investors looking forward to this quarter’s earnings report slated for in July.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend ELEV as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ELEV’s current price about 16.16% and 16.42% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 63.25, while 7-day volatility ratio is 0.56% and 6.38% in the 30-day chart. Further, Elevation Oncology Inc (ELEV) has a beta value of 1.48, and an average true range (ATR) of 0.02. Analysts have given the company’s stock an average 52-week price target of $9, forecast between a low of $8 and high of $10. Looking at the price targets, the low is -2005.26% off current price level while to achieve the yearly target high, price needs to move -2531.58%. Nonetheless, investors will most likely welcome a -2268.42% jump to $9 which is the analysts’ median price.
If we refocus on Elevation Oncology Inc (NASDAQ:ELEV), historical trading data shows that trading volumes averaged 1.76 million over the past 3 months. The company’s latest data on shares outstanding shows there are 59.22 million shares.
The 10.50% of Elevation Oncology Inc’s shares are in the hands of company insiders while institutional holders own 47.23% of the company’s shares. Current price change has pushed the stock -32.15% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ELEV stock continues to rise going into the next quarter.
